146 related articles for article (PubMed ID: 12519935)
1. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
Benhamou Y; Tubiana R; Thibault V
N Engl J Med; 2003 Jan; 348(2):177-8. PubMed ID: 12519935
[No Abstract] [Full Text] [Related]
2. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
Van Bömmel F; Schernick A; Hopf U; Berg T
Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
[No Abstract] [Full Text] [Related]
3. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
4. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Ristig MB; Crippin J; Aberg JA; Powderly WG; Lisker-Melman M; Kessels L; Tebas P
J Infect Dis; 2002 Dec; 186(12):1844-7. PubMed ID: 12447773
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir helps beat hepatitis B.
TreatmentUpdate; 2003 Jan; 15(1):4. PubMed ID: 12630369
[No Abstract] [Full Text] [Related]
7. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
8. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
de Vries-Sluijs TE; van der Eijk AA; Hansen BE; Osterhaus AD; de Man RA; van der Ende ME
J Clin Virol; 2006 May; 36(1):60-3. PubMed ID: 16418013
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
[TBL] [Abstract][Full Text] [Related]
10. Editorial comment: a tale of two viruses.
Dieterich DT
AIDS Read; 2002 Oct; 12(10):448-9. PubMed ID: 12408102
[No Abstract] [Full Text] [Related]
11. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
van Bömmel F; Wünsche T; Schürmann D; Berg T
Hepatology; 2002 Aug; 36(2):507-8. PubMed ID: 12143063
[No Abstract] [Full Text] [Related]
12. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Bani-Sadr F; Palmer P; Scieux C; Molina JM
Clin Infect Dis; 2004 Oct; 39(7):1062-4. PubMed ID: 15472862
[TBL] [Abstract][Full Text] [Related]
13. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
14. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
15. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir therapy for lamivudine resistance following liver transplantation.
Neff GW; Nery J; Lau DT; O'Brien CB; Duncan R; Shire NJ; Ruiz P; Nery C; Montalbano M; Muslu H; Safdar K; Schiff ER; Tzakis AG; Madariaga JR
Ann Pharmacother; 2004 Dec; 38(12):1999-2004. PubMed ID: 15507498
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
[TBL] [Abstract][Full Text] [Related]
18. Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
Matthews GV; Dore GJ
AIDS; 2007 Mar; 21(6):777-8. PubMed ID: 17413705
[No Abstract] [Full Text] [Related]
19. Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Benhamou Y
Clin Infect Dis; 2004 Mar; 38 Suppl 2():S98-103. PubMed ID: 14986281
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]